Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S 55746 in Refractory/Relapsed CLL and B-Cell NHL
NCT02920697Phase 1Completed
- Sponsor
- Servier
- Start
- Mar 2014
- Primary completion
- Oct 2018
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 1, open-label trial of S55746 in chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma and multiple myeloma (MM) (2 arms), sponsored by Servier. Primary endpoints: Maximum Tolerated Dose and Incidence of Adverse Events. Started Mar 2014; status: completed.
02
Drugs
S55746
03
Conditions
chronic lymphocytic leukemia (CLL)B-cell non-Hodgkin lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT02920697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920697.